Yuyu Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 15, 2021 at 02:01 am EST
Share
Yuyu Pharma, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported negative sales was KRW 0.00042 million compared to sales of KRW 0.00009 million a year ago. Net loss was KRW 586.25 million compared to net income of KRW 683.42 million a year ago. Basic loss per share from continuing operations was KRW 41 compared to basic earnings per share from continuing operations of KRW 53 a year ago. Diluted loss per share from continuing operations was KRW 41 compared to diluted earnings per share from continuing operations of KRW 53 a year ago. Basic loss per share was KRW 41 compared to basic earnings per share of KRW 106 a year ago.
For the nine months, negative sales was KRW 0.00001 million compared to KRW 0.00011 million a year ago. Net loss was KRW 466.55 million compared to net income of KRW 1,780.3 million a year ago. Basic loss per share from continuing operations was KRW 43 compared to basic earnings per share from continuing operations of KRW 134.5 a year ago. Diluted loss per share from continuing operations was KRW 43 compared to diluted earnings per share from continuing operations of KRW 134.5 a year ago. Basic loss per share was KRW 43 compared to basic earnings per share of KRW 269 a year ago.
Yuyu Pharma, Inc. is a Korea-based company engaged in the provision of pharmaceutical products. The Company produces prescription drugs such as circulatory improvement agents, antiplatelet agents, osteoporosis drugs, antiulcerants, bone metabolism ameliorants, gout preparative drugs, antidepressants, anti-diabetic agents, antitubercular agents, antihypertensive agents, angina pectoris drugs, antibiotics, hemorrhoidal and varicose preparations, topical corticosteroids and others, as well as non-prescription drugs such as vitamins and digestive agents. It also provides healthcare supplements and quasi drugs. In addition, the Company is involved in the provision of medicines for geriatric diseases such as osteoporosis, dementia, stroke and others.
YUYU PHARMA, INC. 
